Diabetes Drugs Market Research Reports

"...... n 2028, with a CAGR of 6.82% during the forecast years. Insulin glargine, marketed under the names Lantus among others, is a long-acting insulin, used in the treatment of type I and type II diabetes. This report covers a ......"

"...... a glycemic control system that keeps blood glucose at the right level in healthy individual. Glucagon is a medicine which used to treat severe low blood sugar (hypoglycemia). Glucagon works by telling your body to release sugar (glucose) into the bl......"

"...... 18 to 26 hours, with a "peakless" profile (according to the insulin glargine package insert). The Global Insulin Glargine Market Size was estimated at USD 8856.10 million in 2022 and is projected to reach USD 11654.02 million by 2029, exhibiti......"

"...... projected to reach USD 10600.27 million by 2029, exhibiting a CAGR of 2.30% during the forecast period. This report provides a deep insight into the global Dipeptidyl Peptidase-4 (DPP-4) Inhibitors market covering all its essential aspects. Th......"

"...... causing hypoglycemia. The Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size was estimated at USD 8816.20 million in 2022 and is projected to reach USD 21129.58 million by 2029, exhibiting a CAGR of 13.30% during the forecast period. ......"

"...... any - Zealand Pharma - Sanofi-Aventis Segment by Type - Tablet - Liquid Injection Segment by Application - Hospital - Clinic - Medical center - Others Cons......"

"...... >By Company - GlaxoSmithKline - Johnson & Johnson - Merck & Co - AstraZeneca - Novartis - Eli Lilly and Company - Boehringer Ingelheim - Takeda Pharmaceutical Company - Sanofi ......"

"...... % during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Glimepiride market, with a systematical description of the status quo and trends of the......"

"...... Dipeptidyl Peptidase-4 Inhibitors), By Route of Administration (Oral, Injectables) and By Indication (Diabetes, Obesity) for the historical period of 2018-2022, the estimated year of 2023 and the forecast period of 2024-2028. The rese......"

"...... SD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches, and market capital flows are compared across scenarios to dem......"